CRISPR Therapeutics AG

CRISPR Therapeutics AG

CRISPR Therapeutics AG

Overview
Date Founded

2013

Headquarters

Baarerstrasse 14, Zug, 6300, CHE

Type of Company

Public

Employees (Worldwide)

304

Industries

Biotechnology

Company Description

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Executives & Employees

Founder

Chief Executive Officer & Director

Senior Vice President & Chief Financial Officer

Chief Operating & Business Officer

General Counsel & Secretary

Executive Vice President & Head of Research & Development

Head-Human Resources

Head of Immuno-Oncology Research & Translation

Head-Technical Operations

Board of Directors

Founder at CRISPR Therapeutics AG

Chief Executive Officer at Rubius Therapeutics, Inc.

Executive Vice President & Chief Financial Officer at Discover Financial Services

Chief Executive Officer & Director at CRISPR Therapeutics AG

Partner, Director at Principia Biopharma, Inc.

Chairman, Managing Director at Versant Venture Management LLC

General Partner, Washington DC at New Enterprise Associates

Scientific Co-Founder at Spark Therapeutics, Inc.

General Counsel & Secretary at CRISPR Therapeutics AG

Paths to CRISPR Therapeutics AG
Potential Connections via
Relationship Science
You
CRISPR Therapeutics AG
Owners & Shareholders
Details Hidden

Versant Venture Management specializes in early-stage investments in medical devices, biotechnology and pharmaceuticals, healthcare services and healthcare information technology. The firm may also consider later-stage opportunities

Details Hidden

Nikko AMA's investment advice is based on the objectives and terms set out in individual client investment management agreements, relevant fund prospectuses or offering memoranda. Specialist teams throughout the Nikko AM Group's global network are dedicated to providing analysis on macro-economic factors, specific asset classes, strategies and styles. The firm's investment strategy group provides macro-economic insight on factors influencing markets, working in conjunction with investment professionals throughout the group's global network. Equity analysts are assigned responsibilities based on geographic regions, sectors or investment styles. The Nikko AM Group's general approach focuses on fundamental bottom up analysis; although it will vary depending on specific requirements of the investment strategy pursued and is tailored accordingly.

Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Recent Transactions
Details Hidden

CRISPR Therapeutics AG issued USD Common Shares

Details Hidden

CRISPR Therapeutics AG issued USD Common Shares

Details Hidden

CRISPR Therapeutics AG issued USD Common Shares

Transaction Advisors
Escrow Agent

Advised onCRISPR Therapeutics AG issued USD Common Shares

Underwriter

Advised onCRISPR Therapeutics AG issued USD Common Shares

Underwriter

Advised onCRISPR Therapeutics AG issued USD Common Shares

Chair, Life Sciences Practice

Advised onCRISPR Therapeutics AG issued USD Common Shares

Legal Advisor

Advised onCRISPR Therapeutics AG issued USD Common Shares

Associate

Advised onCRISPR Therapeutics AG issued USD Common Shares

Advisors & Consultants
Advisor

Founder at Yumanity Therapeutics, Inc.

Senior Advisor

President, Chief Executive Officer & Principal Financial Officer at Merus NV

Publicist

Managing Director at Westwicke Partners LLC

Clients

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA.

Key Stats and Financials As of 2019
Market Capitalization
$3.23B
Total Enterprise Value
$2.58B
Earnings Per Share
$1.17
Net Profit
$66.9M
EBITDA
$51.5M
EBITDAMargin
17.77%
Total Debt
$52.5M
Total Equity
$939M
Enterprise Value Sales
8.9x
Enterprise Value EBITDAOperating
49.04x
TEVNet Income
38.53x
Debt TEV
0.02x
Three Year Compounded Annual Growth Rate Of Revenue
282.76%
Revenue
$290M
Investors
Details Hidden

Versant Venture Management specializes in early-stage investments in medical devices, biotechnology and pharmaceuticals, healthcare services and healthcare information technology. The firm may also consider later-stage opportunities

Details Hidden

New Enterprise Associates (NEA) focuses on investments in the technology and healthcare sectors. The firm's investment strategy spans all stages of a company's growth, from seeding innovations in emerging markets to funding early-stage companies in high-growth markets to fueling the growth of market leaders. NEA actively invests in emerging markets, with emphasis on India and China.NEA's investments in the healthcare sector focus on companies that address unmet or underserved clinical needs and that combine improved clinical outcomes with lower costs to the market. The firm targets three areas including biopharmaceuticals, medical devices and healthcare services. The firm has a history of partnering with companies that have pioneered transformative innovations in healthcare, such as balloon angioplasty and laparoscopic surgeryWithin the technology sector, NEA focuses on investments in the electronics, consumer technology, enterprise mobility, virtualization, tech-enabled services, SaaS and cloud computing industries.

Details Hidden

Clough Capital Partners employs a fundamental research-driven investment process that seeks to earn superior long-term rates of return for their clients relative to broad equity market indices, such as the S&P 500 Index and the Morgan Stanley World Index. The firm invests its clients' assets primarily in equity and equity-related securities in both US and non-US markets. Clough Capital may also invest clients' assets in fixed income securities and other financial instruments including equity and index options, futures, currencies, and commodities. Investments in non-US markets are made primarily through securities that trade on non-US exchanges and through securities that do trade on US exchanges such as ETFs, GDRs and ADRs. Along with capital appreciation, capital preservation is a primary objective. Clough Capital may use hedging strategies to attempt to provide a degree of protection against market declines, such as shorting individual stocks and using index options and futures. In addition, short positions and put options may also be used to implement independent investment strategies. Clough Capital generally expects to keep accounts in a net long position and will also utilize leverage when deemed appropriate.

Suppliers
University of California Investment Services & Portfolio Management | Oakland, CA

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Orgenesis, Inc. Biotechnology | Germantown, MD

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CT) segments. The CDMO segment through MaSTherCell, comprises of comprehensive services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The CT segment includes a technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and trans-differentiating them into pancreatic beta cell-like insulin-producing cells. The company was founded on June 5, 2008 by Sarah Ferber and is headquartered in Germantown, MD.

MaxCyte, Inc. Industrial Machinery & Manufacturing | Gaithersburg, Maryland

MaxCyte, Inc. enages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include MaxCyte STX, MaxCyte VLX, and MaxCyte GT. The company was founded by Douglas A. Doerfler and is headquartered in Gaithersburg, MD.

Competitors
Vertex Pharmaceuticals, Inc. Pharmaceuticals - Boston, MA

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by CRISPR Therapeutics AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of CRISPR Therapeutics AG's profile does not indicate a business or promotional relationship of any kind between RelSci and CRISPR Therapeutics AG.